Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Cardiovascular Disease, Frailty
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cardiovascular diseases (CVD) are a leading cause of morbidity and mortality worldwide. While CVDs are predominantly diseases of aging, age itself does not predict CVD risk; people age at different rates. Frailty is a state of accelerated aging that increases the risk of adverse health outcomes. Frail people are at higher risk of developing CVDs, experiencing complications, and dying from these diseases than fit people of the same age. Indeed, frailty predicts the likelihood of developing CVD independently of traditional risk factors for CVD. It is known that older women are frailer than men and tend to express CVDs differently than men, but whether relationships between frailty and CVD are sex specific is unclear. It is possible that shared pathophysiological mechanisms such as chronic inflammation may help explain links between CVD and frailty. Importantly, the degree of frailty can be modified by lifestyle interventions. For example, sedentary lifestyles, food insecurity, and suboptimal dietary habits can exacerbate frailty whereas diet and exercise interventions can attenuate frailty. The investigators propose that a comprehensive health strategy targeting diet and physical activity to reduce frailty will reduce the risk of cardiovascular disease (CVD), thereby promoting healthy aging. Engaging in physical activity (e.g. exercise) helps improve aerobic fitness, increase muscle mass, promote cardiac regeneration, enhance metabolic function, regulate blood pressure, improve insulin sensitivity, reduce inflammation (a key frailty mechanism), and lessen frailty. High-quality dietary protein is essential to maintain muscle mass/function, preserve mobility, attenuate inflammation, and reduce frailty. Packed with antioxidants such as anthocyanins and flavonoids, with high levels of fiber, vitamins, and minerals, blueberries, a local Nova Scotian food, can help lower blood pressure, improve blood vessel function, reduce inflammation, and help the body utilize dietary protein. These are critical aspects of a strong heart and healthy aging. To date, many frailty intervention studies have been limited by small sample sizes, underrepresentation of women, and/or by testing individual lifestyle modifications rather than synergistic effects; additionally, none have investigated how reducing frailty impacts cardiovascular outcomes. Our goal is to determine if a year-long multidomain intervention of protein, blueberries, and exercise reduces frailty and cardiovascular disease risk in older at-risk Nova Scotians of both sexes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Dietary Supplement: intervention of protein, blueberries — Intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day. An alternate suitable protein powder such as pea protein isolate powder, pumpkin, casein, rice etc. is available for participants who do not eat milk products.
  • Behavioral: Exercise training — Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.

Primary Outcomes

  • Cardiovascular Risk - Echocardiography (Baseline, 12 Months)
  • Inflammatory Markers (Baseline, 12 Months)
  • Frailty (Baseline, 3,6,9, and 12 months)
  • Cardiovascualr Risk: Blood pressure (Baseline, 3, 6, 9, 12 months)
  • Cardiovascualr Risk: Lipid Profile (Baseline, 12 months)
  • Frailty: Clinical Frailty Scale (CFS) (Baseline, 3, 6, 9, 12 months)
  • Frailty: Pictorial Fit to frail Scale (PFFS) (Baseline, 3, 6, 9, 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-15
Completion: 2028-12-31
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Scotia Health Authority
Collaborators: Dalhousie University
Contact Information
Study Contact:
Scott A Grandy, PhD
902-494-4303
Scott.Grandy@Dal.Ca
Olivia Mercer
STRONG@nshealth.ca
QEII Health Sciences Centre, Dickson Building
Scott Grandy, PhD
902-494-4303
grandy@dal.ca
QEII Health Sciences Centre, Dickson Building
Interventions
  • Dietary Supplement: intervention of protein, blueberries — Intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day. An alternate suitable protein powder such as pea protein isolate powder, pumpkin, casein, rice etc. is available for participants who do not eat milk products.
  • Behavioral: Exercise training — Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.
Study Locations (1 sites)
QEII Health Sciences Centre, Dickson Building, Halifax, Nova Scotia B3H 2Y9 Canada
Eligibility Criteria
Inclusion Criteria: * Must be 65 years of age or above * Must be willing to participate in a low to moderate exercise program Exclusion Criteria: * Medical and cognitive conditions that prevent participation in the intervention * Allergies and or dislike of blueberries and/or protein powder
Conditions Pathologic Processes, Diabetes Mellitus,...
Phase NA
Enrollment 177
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) over 12 weeks using a modified platform trial design.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Standard of Care - DFU — Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Single - DFU — Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Double - DFU — Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: Standard of Care - VLU — Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Single - VLU — Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Double - VLU — Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Primary Outcomes

  • Determine the percentage of subjects achieving complete closure of target ulcer over 12 weeks. (1-12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-20
Completion: 2027-01-22
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 177 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: C5 Biomedical
Collaborators: SerenaGroup, Inc.
Principal Investigators:
  • Thomas Serena, MD (PRINCIPAL_INVESTIGATOR) - SerenaGroup, Inc.
Contact Information
Study Contact:
Bennett Rogers
888-960-1343
Brogers@serenagroups.com
Connie Chung, PhD
734-730-3058
Connie@c5biomedical.com
Donna Belette
504-919-3668
dbelette@serenagroups.com
Poirot Podiatry
Interventions
  • Other: Standard of Care - DFU — Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Single - DFU — Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Double - DFU — Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: Standard of Care - VLU — Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
  • Other: AM/Single - VLU — Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study Locations (1 sites)
Poirot Podiatry, Metairie, Louisiana 70001 United States
Eligibility Criteria
Inclusion Criteria for DFU: 1. At least 18 years of age or older. 2. Must have diagnosis of type 1 or 2 Diabetes mellitus. 3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device. 4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit. 5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus. 6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone. 7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable: 1. ABI between 0.7 and \<= 1.3 2. TBI \>= 0.6 3. TCOM \>= 40 mmHg 4. PVR: biphasic 8. If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 9. Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment. 10. Subject must consent to using the prescribed offloading method for the duration of the study. 11. Subject must agree to attend weekly study visits. 12. Subject must be willing and able to participate in the consent process. Exclusion Criteria for DFU: 1. Subject is known to have a life expectancy of \< 6 months. 2. Subject's target ulcer is not secondary to diabetes. 3. Target ulcer is infected or there is cellulitis in the surrounding skin. 4. Target ulcer exposes tendon or bone. 5. Evidence of osteomyelitis complicating the target ulcer. 6. Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy. 7. The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics). 8. Subject is taking hydroxyurea. 9. Subject has applied topical steroids to the ulcer surface within one month of initial screening. 10. Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer. 11. Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit. 12. The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable). 13. The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase. 14. Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer. 15. Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months. 16. Subject has end stage renal disease requiring dialysis. 17. Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days. 18. The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments. 19. Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening. 20. Subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment. Inclusion Criteria for VLU: Potential subjects are required to meet all the following criteria for enrollment in the study. 1. Subjects must be at least 18 years of age or older. 2. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement. 3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit. 4. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks. 5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable: 1. ABI between 0.7 and ≤ 1.3; 2. TBI ≥ 0.6; 3. TCOM ≥ 40 mmHg; 4. PVR: biphasic. 6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 7. The potential subject must agree to attend the weekly study visits required by the protocol. 8. The potential subject must be willing and able to participate in the informed consent process. Exclusion Criteria for VLU: 1. The potential subject is known to have a life expectancy of \< 6 months. 2. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin. 3. The target ulcer exposes tendon or bone. 4. There is evidence of osteomyelitis complicating the target ulcer. 5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics). 6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening. 7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit. 8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable). 9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC. 10. Women who are pregnant or considering becoming pregnant within the next 6 months. 11. The potential subject has end stage renal disease requiring dialysis. 12. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days. 13. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments. 14. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit. 15. The subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment. 16. A subject has a wound with active or latent infection is excluded. 17. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.
Conditions HER2-positive Breast Cancer
Phase Not Applicable
Enrollment 2806
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis. After the appearance of anti-HER2 targeted drugs, the prognosis and survival of these patients were greatly improved. In addition to trastuzumab and pertuzumab, the use of tyrosine kinase inhibitor (TKI) can further improve the survival. The evidence of previous adjuvant TKI anti-HER2 therapy was mainly from ExteNET study. However, due to the limitations of the times, ExteNET research is based on the background of only trastuzumab targeted therapy. Nowadays, there is no evidence that trastuzumab combined patuzumab,use of T-DM1, followed by sequential neratinib can still obtain absolute benefits. Therefore, there is no standard for the use of neratinib in current clinical practice. Investigators want to explore, in the real world, the efficacy and safety of sequential use of naratinib in adjuvant therapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: neratinib — neratinib 240mg qd for 1 year

Primary Outcomes

  • invasive disease free survival (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-01-01
Completion: 2031-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 2806 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shu Wang
Principal Investigators:
  • shu wang, doctor (PRINCIPAL_INVESTIGATOR) - Peking University People's Hospital
Contact Information
Study Contact:
yuan peng, doctor
86+13671287670
13671287670@163.com
yuan peng, Dr
Peking University People's Hospital
Interventions
  • Drug: neratinib — neratinib 240mg qd for 1 year
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: * 1\) Patients with HER2 positive breast cancer who were diagnosed by core needle biopsy/operation in Peking University People's hospital; * 2\) The patients were treated in our hospital and underwent radical resection with hospitalization records; * 3\) Received standard anti-HER2 neoadjuvant/adjuvant therapy (trastuzumab, trastuzumab combined with pertuzumab, T-DM1) * 4\) Has signed and agreed to participate in the PKUPH breast disease cohort study. Exclusion Criteria: * 1\) Lack of clinical and pathological data (such as imaging data and pathological data); * 2\) Patients with metastatic breast cancer or bilateral breast cancer; * 3\) Failure to perform radical surgery
Conditions Well-Being, Psychological
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The psychological, social, and health consequences of psychological ill-being, particularly loneliness, are well-documented among students, which underlines the importance of providing adequate support. Groups 4 Health (G4H) is a promising psychosocial group intervention focused on improving well-being by supporting social connectedness and belonging. In earlier Australian studies G4H has decreased loneliness and social anxiety and increased group memberships significantly more than treatment as usual. When compared to cognitive behavioral therapy G4H has showed continued reduction in the participants' loneliness at the end of the intervention period and in the follow-up. Research on the G4H intervention's effectiveness outside Australia and research on the intervention's cost-effectiveness is lacking. Therefore, this clinical study investigates the feasibility, effectiveness, and cost-effectiveness of the G4H among the University of Helsinki students in Finland. The effectiveness and cost-effectiveness of the G4H will be compared to two other active intervention groups: the well-being groups facilitated by the study psychologists at the University of Helsinki and an online course for students' well-being. Effectiveness will also be compared to students who do not participate in any well-being courses or interventions. The investigators hypothesize that all the active intervention groups promote student well-being. Questionnaires and University of Helsinki registry data will be gathered before and after the interventions to evaluate the effectiveness and cost-effectiveness of the interventions. The factors that influence the intervention's effectiveness and cost-effectiveness will also be studied. In addition to these research questions, qualitative methods are used to explore the challenges and possibilities identified in the G4H-intervention regarding inclusion and equality.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Groups 4 Health (G4H) — Groups 4 Health, G4H, ("Ryhmät kuntoon") at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology MA students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 ECTS (European Credit Transfer and Accumulation System) credits for completing the intervention.
  • Behavioral: The study psychologists' group intervention — University of Helsinki study psychology team organizes group interventions for various challenges of studying for bachelor's and master's students. These groups offer client-centered peer support facilitated by one to two study psychologists. Recurring themes in the groups include: challenges in attentiveness, independent studying, and scientific writing, as well as support for re-entering the studies after a break. The approach in the different thematic groups is largely similar: short presentations, group discussions and practices. These groups have been implemented as both face-to-face and remote meetings. One group typically lasts for a study period and comprises five to six 90 minutes sessions. Typical group size is six to 12 students.
  • Behavioral: Towards better well-being and studying -online course — Towards better well-being and studying -online course ("Kohti parempaa opiskelua") is an optional, seven-week online course that aims to foster university students' well-being and study skills. It is available for all University of Helsinki students. The course is based on principles of Acceptance and Commitment therapy and aims to support the development of psychological flexibility. The course takes place in Moodle platform and the students earn 3 ECTS credits for completing it. This course progresses week by week and has six central themes which include individual work in practicing psychological flexibility skills as well as study skills on a weekly basis and weekly group discussion.

Primary Outcomes

  • Loneliness (1) Before the intervention, 2) During the intervention (week 3), 3) immediately after the intervention, 4) one month follow-up, 5) three months follow-up)
  • Depression (1) Before the intervention, 3) immediately after the intervention 4) one month follow-up, 5) three months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-20
Completion: 2026-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Helsinki
Collaborators: Strategic Research Council, Finland, University of Eastern Finland, Finnish Institute for Health and Welfare
Principal Investigators:
  • Jari M Lahti, PhD (PRINCIPAL_INVESTIGATOR) - University of Helsinki
Contact Information
Study Contact:
Jari M Lahti, PhD
040 571 2297
jari.lahti@helsinki.fi
Silja A Martikainen, PhD
044 353 1984
silja.martikainen@helsinki.fi
Jari M Lahti, PhD
040 571 2297
jari.lahti@helsinki.fi
University of Helsinki
Interventions
  • Behavioral: Groups 4 Health (G4H) — Groups 4 Health, G4H, ("Ryhmät kuntoon") at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology MA students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 ECTS (European Credit Transfer and Accumulation System) credits for completing the intervention.
  • Behavioral: The study psychologists' group intervention — University of Helsinki study psychology team organizes group interventions for various challenges of studying for bachelor's and master's students. These groups offer client-centered peer support facilitated by one to two study psychologists. Recurring themes in the groups include: challenges in attentiveness, independent studying, and scientific writing, as well as support for re-entering the studies after a break. The approach in the different thematic groups is largely similar: short presentations, group discussions and practices. These groups have been implemented as both face-to-face and remote meetings. One group typically lasts for a study period and comprises five to six 90 minutes sessions. Typical group size is six to 12 students.
  • Behavioral: Towards better well-being and studying -online course — Towards better well-being and studying -online course ("Kohti parempaa opiskelua") is an optional, seven-week online course that aims to foster university students' well-being and study skills. It is available for all University of Helsinki students. The course is based on principles of Acceptance and Commitment therapy and aims to support the development of psychological flexibility. The course takes place in Moodle platform and the students earn 3 ECTS credits for completing it. This course progresses week by week and has six central themes which include individual work in practicing psychological flexibility skills as well as study skills on a weekly basis and weekly group discussion.
Study Locations (1 sites)
University of Helsinki, Helsinki, Uusimaa 00014 Finland
Eligibility Criteria
Inclusion criteria * Adult (age 18 and above) * Student in the University of Helsinki, Finland * Able to speak/read Finnish, Swedish, or English Exclusion criteria: \- None
Conditions Treatment Resistant Depression
Phase NA
Enrollment 100
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Sham-stimulation — Sham-stimulation
  • Device: Active-stimulation — Active DBS

Primary Outcomes

  • Change in MADRS total score (12 months)
  • CGI-I response rate (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-11
Completion: 2029-04
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abbott Medical Devices
Principal Investigators:
  • Brian Kopell, MD (PRINCIPAL_INVESTIGATOR) - MOUNT SINAI HOSPITAL
  • Mark George, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Natalie Danovsky
+16517563842
natalie.richardson@abbott.com
Lyndahl Himes
lyndahl.himes@abbott.com
Kristine Pike
2059758542
kristinepike@uabmc.edu
University of Alabama at Birmingham - Dept. of Psychiatry
Interventions
  • Device: Sham-stimulation — Sham-stimulation
  • Device: Active-stimulation — Active DBS
Study Locations (25 sites)
University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham, Alabama 35294 United States
USC University Hospital, Los Angeles, California 90033 United States
UCLA Department of Psychiatry, Los Angeles, California 90095 United States
University of California at Davis, Sacramento, California 95817 United States
USF Health, Tampa, Florida 33613 United States
Emory University Hospital, Atlanta, Georgia 30322 United States
Rush University Medical Center, Chicago, Illinois 60612 United States
Indiana University, Indianapolis, Indiana 46202 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: 1. The patient must be diagnosed with non-psychotic unipolar Major Depressive Disorder. 2. The patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes. 3. The patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose. 4. Depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit Exclusion Criteria: 1. Pregnant or those who plan to become pregnant during study 2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol. 3. Current or lifetime history of psychotic features in any Major Depressive Episode. 4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication. 5. Significant acute suicide risk. 6. Diagnosis of Substance Use Disorder or Alcohol Use Disorder without sustained remission (12 months or longer). 7. Current and ongoing use of neurostimulation treatment that may interfere with DBS therapy/system. 8. Treatment with another investigational device or investigational drugs.

DPA-714 and FDG PET/MRI in Depression

NCT06565936
Recruiting
Conditions Depression
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Radiation: PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG — Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Primary Outcomes

  • Assessment of baseline and follow up regional brain TSPO levels and cerebral metabolism using PET/MRI (for 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-23
Completion: 2026-12
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Dalian Medical University
Principal Investigators:
  • Huimin Zhang (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Dalian Medical University
Contact Information
Study Contact:
Huimin Zhang
+86 18098876233
huiminzhangxs@163.com
Hui min Zhang
+86 18098876233
huiminzhangxs@163.com
The First Affiliated Hospital of Dalian Medical University
Mei chen Liu
+86 18098871637
meichenliu9019@163.com
The First Affiliated Hospital of Dalian Medical University
Interventions
  • Radiation: PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG — Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
Study Locations (1 sites)
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000 China
Eligibility Criteria
Inclusion Criteria: 1. For all groups : * No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination * MMSE≥24 points,MOCA≥26 points * No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks * Patients with diabetes had fasting controlled below 9.0mmol/L before the examination * Volunteer to participate in the study and sign the informed consent 2. For Recurrent depression patients: * Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * Age 35-85 years old, gender is not limited * HAMD≥8 points 3. For first episode depression Patients: * Gender, age and education level were matched with the recurrent depression group * Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD≥8 points 4. For controls: * Healthy people undergoing "DPA-714 or FDG imaging PET/MRI" physical examination in PET/CT room of our hospital * Gender and education level were consistent with both the recurrent depression group and the first-episode depression group * never used any psychotropic drugs * HAMD\<8 points;HAMA\<7 points Exclusion Criteria(for all groups): * Have a history of organic mental disorders or other mental disorders * A family history of hereditary diseases * Persons with mental retardation or dementia * A history of psychoactive substance abuse * Can not cooperate with/complete the psychological examination scale * Previously found serious physical diseases (heart, brain, liver, lung and kidney) * MRI contraindications, abnormalities found in head CT or MRI * A history of drug or alcohol abuse * Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases * are in the state of pregnancy or breastfeeding
Conditions Herpes Zoster
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Hospital Anxiety and Depression Scale — Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.

Primary Outcomes

  • HADS score (during hospital stay, average of 1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-21
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Huazhong University of Science and Technology
Principal Investigators:
  • Yang Shuguang, M.D (PRINCIPAL_INVESTIGATOR) - Tongji medical college of Huazhong University of Science and technology
Contact Information
Study Contact:
Yang Shuguang, M.D
(+86)15071078161
yangsuperpro@163.com
Mei wei, M.D, PhD
(+86)13006162508
wmei@hust.edu.cn
Yang Shuguang, Master
15071078161
yangsuperpro@163.com
Tongji hospital
Interventions
  • Diagnostic Test: Hospital Anxiety and Depression Scale — Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
Study Locations (1 sites)
Tongji hospital, Wuhan, Hubei 430031 China
Eligibility Criteria
Inclusion Criteria: 1. Age more than 18 years old 2. Diagnosed as herpes zoster neuralgia 3. Signing informed consent Exclusion Criteria: 1. Unable to complete the scale assessment 2. History of mental illness
Conditions Treatment Resistant Depression
Phase PHASE2
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as risperidone. The purpose of this study is to use an established SV2A radiotracer produced at our Centre to determine the feasibility of integrating PET imaging in to psilocybin trials. The preliminary imaging data will assess whether psilocybin's antidepressant effects are related to changes in synaptic density in adults with TRD, and whether any changes in synaptic density are associated with psilocybin's actions on the 5-HT2AR.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin 25 mg — The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
  • Drug: Risperidone 1 MG — The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.

Primary Outcomes

  • Feasibility of obtaining PET imaging scans before and after administration of psilocybin (25 mg) with and without risperidone (1 mg) in adults with TRD. (Screening to end of follow up (Day 28))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-21
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Addiction and Mental Health
Principal Investigators:
  • Ishrat Husain, MBBS, MD (PRINCIPAL_INVESTIGATOR) - Centre for Addiction and Mental Health
Contact Information
Study Contact:
Emily Gilbert, MSc
416-535-8501
emily.gilbert@camh.ca
Psychedelics Research
psychedelics.research@camh.ca
Emily Gilbert, MSc
416-535-8501
emily.gilbert@camh.ca
Centre for Addiction and Mental Health
Interventions
  • Drug: Psilocybin 25 mg — The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
  • Drug: Risperidone 1 MG — The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.
Study Locations (1 sites)
Centre for Addiction and Mental Health, Toronto, Ontario M6J1H4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Adults 18 to 65 years old; 2. Must be deemed to have capacity to provide informed consent; 3. Must sign and date the informed consent form; 4. Stated willingness to comply with all study procedures; 5. Ability to read and communicate in English, such that their literacy and comprehension is sufficient for understanding the consent form and study questionnaires, as evaluated by study staff obtaining consent; 6. Primary DSM-5 diagnosis of non-psychotic MDD, single or recurrent, based on the Structured Clinical Interview for DSM-5 (SCID-5) administered at the first screening visit; 7. Participants diagnosed with treatment-resistant depression defined as individuals with a baseline HamD-17 score \> 14 and that have not responded to two or more separate trials of antidepressants at an adequate dosage and duration (an antidepressant resistance rating score of three or more is considered an adequate trial) based on the Antidepressant Treatment History Form (ATHF); there is no upper limit on the number of treatment failures; 8. Ability to take oral medication; 9. Individuals who are capable of becoming pregnant: use of highly effective contraception for at least 3 months prior to screening and agreement to use such a method during study participation; 10. Individuals who are willing to taper off current antidepressant and antipsychotic medications for a minimum of 2-weeks (or more depending on the medication) prior to Baseline (V2) and whose physician confirms that it is safe for them to do so; and 11. Agreement to adhere to Lifestyle Considerations (section 4.5) throughout study duration. Exclusion Criteria: 1. Pregnant as assessed by a urine pregnancy test at Screening (V1) or individual's that intend to become pregnant during the study or are breastfeeding; 2. Treatment with another investigational drug or other intervention within 30 days of Screening (V1); 3. Have initiated psychotherapy in the preceding 12 weeks prior to Screening (V1); 4. Have a DSM-5 diagnosis of substance use disorder (use of tobacco is permitted) within the preceding 6 months; 5. Have active suicidal ideation with intent and plan as determined by item 3 of the HamD-17; 6. Any DSM-5 lifetime diagnosis of a schizophrenia-spectrum disorder; obsessive-compulsive disorder, psychotic disorder (unless substance induced or due to a medical condition), bipolar I or II disorder, paranoid personality disorder, borderline personality disorder, or neurocognitive disorder as determined by medical history and the SCID-5 clinical interview; 7. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I disorder as determined by the family medical history form and discussions with the participant; 8. Presence of a relative or absolute contraindication to psilocybin, including a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment. 9. Presence of baseline prolonged QTc or Torsade de Pointes as measured by the ECG or a history of long QTc syndrome or related risk factors; 10. History of allergy or contraindication to risperidone 11. Current or past traumatic brain injury or other neurological/neurodegenerative disorder 12. Unable or unwilling to undergo PET or MRI scanning (e.g. claustrophobia, pacemaker); 13. Blood disorders, disorders of coagulation, or ongoing use of anticoagulant medication 14. Any disability that may prevent the participant from completing study requirements (e.g., non-correctable clinically significant sensory impairment such as not hearing well enough to communicate with study personnel during scans, or physical disability that does not allow them to lie still on the scanner bed for 1-2 hours); 15. Participant exceeds the annual or lifetime amount of radiation 16. Any other clinically significant physical illness including chronic infectious diseases or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.
Conditions Essential Hypertension
Phase PHASE3
Enrollment 251
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: AD-227A — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: AD-227B — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: AD-227C — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: Placebo of AD-227B — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: Placebo of AD-227C — Per Oral, 1 Tablet, Once a day for 8 weeks

Primary Outcomes

  • Change in MSSBP (Baseline to Week8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-07-31
Completion: 2025-09
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 251 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Addpharma Inc.
Principal Investigators:
  • Chong-Jin Kim (PRINCIPAL_INVESTIGATOR) - Gangnam CHA Medical Center
Contact Information
Study Contact:
JeongEun Park
+82-31-891-6989
parkje@addpharma.co.kr
Interventions
  • Drug: AD-227A — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: AD-227B — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: AD-227C — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: Placebo of AD-227B — Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug: Placebo of AD-227C — Per Oral, 1 Tablet, Once a day for 8 weeks
Study Locations (1 sites)
Gangnam CHA Medical Center, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied
Conditions Advanced Unresectable or Metastatic Brea...
Phase PHASE1, PHASE2
Enrollment 528
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-6209 in Combination with Fulvestrant — HRS-6209 in Combination with Fulvestrant
  • Drug: HRS-6209 in Combination with HRS-1358 — HRS-6209 in Combination with HRS-1358
  • Drug: HRS-6209 in Combination with Letrozole — HRS-6209 in Combination with Letrozole
  • Drug: HRS-6209 in Combination with HRS-8080 — HRS-6209 in Combination with HRS-8080
  • Drug: HRS-6209 in Combination with HRS-1358 — HRS-6209 in Combination with HRS-1358
  • Drug: HRS-6209 in Combination with HRS-9813 and Letrozole — HRS-6209 in Combination with HRS-9813 and Letrozole
  • Drug: HRS-6209 in Combination with HRS-9813 and HRS-8080 — HRS-6209 in Combination with HRS-9813 and HRS-8080

Primary Outcomes

  • DLT (dose-limiting toxicity)-Stage I (dose exploration) (28 days after the first dose)
  • MTD (maximum tolerated dose) -Stage I (dose exploration) (28 days after the first dose)
  • RP2D (recommended phase II dose) -Stage I (dose exploration) (28 days after the first dose)
  • (Serious) AEs-Stage I (dose exploration) (every week in Cycle 1 (28 days after the first dose), every 2 weeks in Cycle 2 (28 days after the second dose), every 4 weeks from Cycle 3 and thereafter (28 days after each dose), lasting about one year)
  • ORR ( objective response rate )-Stage II (efficacy expansion) (every 8 weeks lasting about one year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-08-12
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 528 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Contact Information
Study Contact:
Xiaonan Sheng
+86 13524857678
xiaonan.sheng.xs6@hengrui.com
Jiong Wu
Fudan University Shanghai Cancer Center
Interventions
  • Drug: HRS-6209 in Combination with Fulvestrant — HRS-6209 in Combination with Fulvestrant
  • Drug: HRS-6209 in Combination with HRS-1358 — HRS-6209 in Combination with HRS-1358
  • Drug: HRS-6209 in Combination with Letrozole — HRS-6209 in Combination with Letrozole
  • Drug: HRS-6209 in Combination with HRS-8080 — HRS-6209 in Combination with HRS-8080
  • Drug: HRS-6209 in Combination with HRS-1358 — HRS-6209 in Combination with HRS-1358
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Females aged 18-75 years (inclusive); 2. ECOG performance status (PS) score of 0-1; 3. Patients with histopathologically confirmed metastatic or unresectable locally advanced breast cancer; 4. Patients with advanced malignant solid tumors confirmed by histopathology or cytopathology, who have failed standard treatment, or for whom no effective standard treatment regimen is available, or who are unable to receive further standard treatment. 5. Menopausal status: 1. Having had bilateral oophorectomy, or aged ≥ 60 years old; or 2. Aged \< 60, natural menopause (defined as spontaneous cessation of regular menses for at least 12 consecutive months in the absence of other pathological or physiological causes) with E2 and FSH at postmenopausal levels; or 3. Premenopausal or perimenopausal patients, agree to start or continue receive LHRH agonists during the study (exclude from the QT/QTc group). 6. Disease progression evidenced by imaging during or after the last systemic anti-tumor treatment prior to the first dose (limited to the efficacy expansion stage); 7. With at least one extracranial measurable target lesion at baseline per RECIST v1.1; 8. Life expectancy of \> 3 months; 9. Adequate organ and marrow function as defined by the protocol;Female subjects of childbearing potential should agree to adopt effective contraceptive measures during the study period and within 7months after the end of the study treatment; female subjects of childbearing potential must have a negative serum HCG test result within 7 days before enrollment in the study and must not be in the lactation; 10. Voluntarily participate in this clinical study, be willing and able to comply with procedures related to clinical visits and study, and understand and have signed written informed consent. Exclusion Criteria: 1. With symptomatic visceral metastases deemed unfit for endocrine therapy by the investigator; 2. With active brain metastases, carcinomatous meningitis, spinal cord compression, or a history of primary tumors of the central nervous system; 3. History of clinically significant cardiovascular disease, including; 4. Abnormal ECG findings, which are judged by the investigator to be clinically significant and and need to intervene; 5. Previous use of fulvestrant for cohort of HRS-6209 in combination with fulvestrant (efficacy expansion stage). 6. With factors that affect oral medication, active gastrointestinal diseases, or other diseases that may obviously affect drug absorption, distribution, metabolism, or excretion; 7. With clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding; 8. Active infection or unexplained fever \> 38.5 °C during the screening period or on the day of first dose; 9. With uncontrollable chronic systemic complications as judged by the investigator. 10. With active autoimmune diseases, history of immunodeficiency and history of autoimmune diseases, history of diseases or syndromes that require systemic corticosteroids or immunosuppressive drugs, other acquired (HIV infection) or congenital immunodeficiency, or history of organ transplantation (including allogeneic bone marrow transplantation); 11. With acute infection or active tuberculosis requiring medication. 12. With a known history of clinically significant liver disease, untreated active hepatitis; 13. Had other concurrent malignant tumors in the past 5 years, except: 1. Cervical carcinoma in situ that has been cured, 2. Second primary cancer that has been cured without recurrence within five years; 14. Use of moderate and strong CYP3A4 inhibitors within 1 week or moderate and strong CYP3A4 inducers within 2 weeks prior to the first dose; 15. Use of any drugs with the risk of prolonging QT/QTc interval or causing torsade de pointes (TdP) within 4 weeks prior to the first dose, and with previous congenital QT interval prolongation syndrome or a family history of QT interval prolongation, implanted pacemakers or automatic implantable cardioverter defibrillators, uncorrectable electrolyte disorders, and other factors that may affect the QT/QTc study; 16. Surgical treatment (except for needle biopsy or PICC catheterization or PORT catheterization), chemotherapy (except for 5-Fu drugs), immunotherapy, macromolecular targeted therapy, etc. within 4 weeks before the first dose; Received endocrine therapy, 5-FU chemotherapy or radiotherapy within 2 weeks before the first dose; Small molecule targeted drugs need to be washed out for 2 weeks or 5 half-lives (whichever is longer); 17. Pregnant or lactating women, or females planning to become pregnant during the study period; 18. With clear history of neural or mental disorders or with history of psychotropic abuse or drug abuse; 20\) Subjects who are expected to receive other anti-tumor therapies or drugs during this study.
Conditions Triple Negative Breast Cancer
Phase PHASE1, PHASE2
Enrollment 51
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ProAgio Dose Levels (DL) 1,2,3,4 — ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
  • Drug: ProAgio Dose Expansion — ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.

Primary Outcomes

  • Part 1 (Dose Escalation) (2 Years)
  • Part 2 (Dose Expansion) (2 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-08-20
Completion: 2027-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 51 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ProDa BioTech, LLC
Collaborators: Emory University, Georgia State University
Principal Investigators:
  • Kevin Kalinsky, M.D, M.S (PRINCIPAL_INVESTIGATOR) - Emory University Winship Cancer Institute
Contact Information
Study Contact:
Damon Michaels
615-614-1185
damon.michaels@medelis.com
Zhi-Ren Liu
zliu8@gsu.edu
Ashley Trumbull
404-778-3969
ashley.lynn.trumbull@emory.edu
Winship Cancer Institute of Emory University
Interventions
  • Drug: ProAgio Dose Levels (DL) 1,2,3,4 — ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
  • Drug: ProAgio Dose Expansion — ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
Study Locations (2 sites)
Emory University Winship Cancer Institute, Atlanta, Georgia 30322 United States
Winship Cancer Institute of Emory University, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Adult participants, ≥ 18 years of age, with histologically or cytologically confirmed metastatic breast cancer that is estrogen receptor (ER) negative (less than 10%), progesterone receptor (PR) negative (less than 10%), and HER2 negative/unamplified as per ASCO/CAP guidelines (Wolff et al., 2018). If ER/PR less than 10%, prior endocrine therapy is permitted, and the participant is not considered appropriate for hormone based therapy. Participants must agree to provide archival tumor material from metastatic site (most recent archival tumor tissue immediately prior to enrollment is strongly preferred) and must agree to undergo research tumor biopsy before treatment and during cycle 2 at the same site of metastatic disease, if presence of easily accessible lesion, at the discretion of the treating physician. * Participants must have received at least two lines of prior systemic treatment for advanced disease. If participants received systemic therapy in the operable setting and the tumor progressed within 12 months of the receipt of the last dose of systemic therapy, this will be considered one line of prior systemic therapy for advance disease. Participants must be more than 14 days removed from most recent standard of care or experimental drug treatment for their tumor. * ECOG performance status ≤2 * Participants must have adequate organ and marrow function as defined below: * Absolute neutrophil count ≥1,500/mcL * Hemoglobin ≥9 g/ dL (recent transfusion allowed) * Platelets ≥100,000/mcL * AST(SGOT)/ALT(SGPT) ≤3 x ULN. AST and ALT (up to 5x ULN is permitted for participants with liver metastases) * Total bilirubin ≤1.5 x institutional ULN * Creatinine clearance ≥60 mL/min (measured using Cockcroft- Gault equation or the estimated glomerular filtration rate) * Participants with CNS metastases must be treated and/or stable (no progression for at least 4 weeks after local prior therapy as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period). Those with symptoms suggestive of possible CNS metastases (such as new headaches) must undergo brain MRI as part of screening. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * The effects of ProAgio on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for the 6 months following the last dosing of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * During dose escalation, participants with bone only and/or non-measurable disease are eligible. During dose expansion, only participants with measurable disease are eligible. * Ability of subject to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participants who have had prior treatment with gemcitabine in the metastatic setting. * Platelet transfusion within 7 days prior to treatment start. * Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients with history of known congestive heart failure (left ventricular ejection fraction (LVEF) \<50%) must have documented LVEF \>50% within 12 months of study enrollment. * Prolonged QTc interval \>480 msec on screening EKG * Participants with known diagnosis of a chronic neurologic disorders (such as multiple sclerosis, Huntington's disease, Parkinson's disease, or uncontrolled epilepsy) which causes motor disturbance, visual disturbance, or seizure and could confound assessment of neurologic toxicity caused by the study drug. * Pregnant or nursing women are excluded from this study because ProAgio is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ProAgio, breastfeeding should be discontinued if the mother is treated with ProAgio. * Participants who have undergone a major surgical procedure (within \< 28 days) are excluded. * Participants with uncontrolled bleeding episodes \<28 days prior to enrollment are excluded.
Conditions Hypertension
Phase NA
Enrollment 460
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is to determine if hypertension management by community health workers (CHW) supported by a mobile health application and remote physician supervision is non-inferior to management by a physician for the primary outcome of improvement in systolic blood pressure. The target population is patients with hypertension in rural Guatemala. Study duration will be 12-24 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: CommCare with Mobile Clinical Decision Support (CDS) Application — For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
  • Other: Remote Supervision by Physicians — teleconsultation with a supervising physician
  • Other: CommCare Application without CDS — The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.

Primary Outcomes

  • Change in Systolic Blood Pressure (SBP) (Baseline, 6 months, 12 months (all participants assessed to 6 months, but participants on study early may also be assessed at 12, 18 and 24 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-09
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 460 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Collaborators: Fogarty International Center of the National Institute of Health
Principal Investigators:
  • Sean Duffy, MD (PRINCIPAL_INVESTIGATOR) - University of Wisconsin, Madison
Contact Information
Study Contact:
Sean Duffy, MD
608-354-7930
sean.duffy@fammed.wisc.edu
Interventions
  • Other: CommCare with Mobile Clinical Decision Support (CDS) Application — For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
  • Other: Remote Supervision by Physicians — teleconsultation with a supervising physician
  • Other: CommCare Application without CDS — The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
Study Locations (1 sites)
Community, San Lucas Tolimán, Guatemala
Eligibility Criteria
Inclusion Criteria: * Adults age 18 or greater with diagnosis of hypertension AND blood pressure (BP) greater than or equal to 140/90 OR currently taking antihypertensive medication. * Ability to provide informed consent Exclusion Criteria: * Pregnancy * Severe comorbid condition(s) with life expectancy less than 1 year